Diabetes specialist Dexcom chooses Exyte to build first facility in Asia

The US-based diabetes care technology provider has planned 1.8m sqft of manufacturing space in Malaysia

Exyte, a high-tech facility design and construction specialist, has been awarded a fast-track project for Dexcom in Penang, Malaysia. This is the first manufacturing facility for the US-based diabetes care technology provider outside the United States.

Exyte is supporting Dexcom's strategic growth plans as it expands manufacturing into Asia for the first time. Located in Batu Kawan, Penang, and with 1.8 million sqft of gross floor area, the project will house a manufacturing facility for continuous glucose monitoring (CGM) systems.

Key parts of the facility include:

  • multi-story cleanrooms
  • a warehouse with dock leveller
  • a three-story Central Utility Building (CUB)
  • a seven-story office building with a canteen and recreational area as well as a seven-level multi-story parking structure

The project will enable Dexcom to quickly expand CGM production, increasing the number of systems it can deliver worldwide to meet growing demands.

"We selected Exyte as the construction partner for our first manufacturing facility in Asia due to their excellent record of delivering fast-track projects of this magnitude and complexity," said David Arida, Senior VP of Manufacturing Operations at Dexcom.

Jack Lyons, VP of Biopharma and Life Sciences Southeast Asia at Exyte shared: "We are delighted to be selected as the main contractor and trusted partner in delivering the first manufacturing facility for Dexcom in Asia and enabling a quick time to market for our client."

Companies